Literature DB >> 25114226

MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.

Brian J Gill1, David J Pisapia2, Hani R Malone1, Hannah Goldstein1, Liang Lei2, Adam Sonabend1, Jonathan Yun1, Jorge Samanamud1, Jennifer S Sims1, Matei Banu1, Athanassios Dovas2, Andrew F Teich2, Sameer A Sheth1, Guy M McKhann1, Michael B Sisti1, Jeffrey N Bruce3, Peter A Sims4, Peter Canoll5.   

Abstract

Glioblastomas (GBMs) diffusely infiltrate the brain, making complete removal by surgical resection impossible. The mixture of neoplastic and nonneoplastic cells that remain after surgery form the biological context for adjuvant therapeutic intervention and recurrence. We performed RNA-sequencing (RNA-seq) and histological analysis on radiographically guided biopsies taken from different regions of GBM and showed that the tissue contained within the contrast-enhancing (CE) core of tumors have different cellular and molecular compositions compared with tissue from the nonenhancing (NE) margins of tumors. Comparisons with the The Cancer Genome Atlas dataset showed that the samples from CE regions resembled the proneural, classical, or mesenchymal subtypes of GBM, whereas the samples from the NE regions predominantly resembled the neural subtype. Computational deconvolution of the RNA-seq data revealed that contributions from nonneoplastic brain cells significantly influence the expression pattern in the NE samples. Gene ontology analysis showed that the cell type-specific expression patterns were functionally distinct and highly enriched in genes associated with the corresponding cell phenotypes. Comparing the RNA-seq data from the GBM samples to that of nonneoplastic brain revealed that the differentially expressed genes are distributed across multiple cell types. Notably, the patterns of cell type-specific alterations varied between the different GBM subtypes: the NE regions of proneural tumors were enriched in oligodendrocyte progenitor genes, whereas the NE regions of mesenchymal GBM were enriched in astrocytic and microglial genes. These subtype-specific patterns provide new insights into molecular and cellular composition of the infiltrative margins of GBM.

Entities:  

Keywords:  glioma; microenvironment; tumor heterogeneity

Mesh:

Substances:

Year:  2014        PMID: 25114226      PMCID: PMC4151734          DOI: 10.1073/pnas.1405839111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Age-dependent sensitivity of the developing brain to irradiation is correlated with the number and vulnerability of progenitor cells.

Authors:  Aya Fukuda; Hirotsugu Fukuda; Janos Swanpalmer; Sven Hertzman; Birgitta Lannering; Ildiko Marky; Thomas Björk-Eriksson; Klas Blomgren
Journal:  J Neurochem       Date:  2005-02       Impact factor: 5.372

2.  Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth.

Authors:  Alexander Pietras; Amanda M Katz; Elin J Ekström; Boyoung Wee; John J Halliday; Kenneth L Pitter; Jillian L Werbeck; Nduka M Amankulor; Jason T Huse; Eric C Holland
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

3.  Cell type-specific gene expression differences in complex tissues.

Authors:  Shai S Shen-Orr; Robert Tibshirani; Purvesh Khatri; Dale L Bodian; Frank Staedtler; Nicholas M Perry; Trevor Hastie; Minnie M Sarwal; Mark M Davis; Atul J Butte
Journal:  Nat Methods       Date:  2010-03-07       Impact factor: 28.547

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function.

Authors:  John D Cahoy; Ben Emery; Amit Kaushal; Lynette C Foo; Jennifer L Zamanian; Karen S Christopherson; Yi Xing; Jane L Lubischer; Paul A Krieg; Sergey A Krupenko; Wesley J Thompson; Ben A Barres
Journal:  J Neurosci       Date:  2008-01-02       Impact factor: 6.167

7.  Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.

Authors:  Rebecca Favaro; Irene Appolloni; Serena Pellegatta; Alexandra Badiola Sanga; Pierfrancesco Pagella; Eleonora Gambini; Federica Pisati; Sergio Ottolenghi; Maria Foti; Gaetano Finocchiaro; Paolo Malatesta; Silvia K Nicolis
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

8.  Patterns of gene-specific and total transcriptional activity during the Plasmodium falciparum intraerythrocytic developmental cycle.

Authors:  Jennifer S Sims; Kevin T Militello; Peter A Sims; Vishal P Patel; Jacob M Kasper; Dyann F Wirth
Journal:  Eukaryot Cell       Date:  2009-01-16

9.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  108 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner.

Authors:  Hannah S Picariello; Rajappa S Kenchappa; Vandana Rai; James F Crish; Athanassios Dovas; Katarzyna Pogoda; Mariah McMahon; Emily S Bell; Unnikrishnan Chandrasekharan; Amanda Luu; Rita West; Jan Lammerding; Peter Canoll; David J Odde; Paul A Janmey; Thomas Egelhoff; Steven S Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

4.  Clonal evolution of glioblastoma under therapy.

Authors:  Jiguang Wang; Emanuela Cazzato; Erik Ladewig; Veronique Frattini; Daniel I S Rosenbloom; Sakellarios Zairis; Francesco Abate; Zhaoqi Liu; Oliver Elliott; Yong-Jae Shin; Jin-Ku Lee; In-Hee Lee; Woong-Yang Park; Marica Eoli; Andrew J Blumberg; Anna Lasorella; Do-Hyun Nam; Gaetano Finocchiaro; Antonio Iavarone; Raul Rabadan
Journal:  Nat Genet       Date:  2016-06-06       Impact factor: 38.330

5.  Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Authors:  Zev A Binder; Amy Haseley Thorne; Spyridon Bakas; E Paul Wileyto; Michel Bilello; Hamed Akbari; Saima Rathore; Sung Min Ha; Logan Zhang; Cole J Ferguson; Sonika Dahiya; Wenya Linda Bi; David A Reardon; Ahmed Idbaih; Joerg Felsberg; Bettina Hentschel; Michael Weller; Stephen J Bagley; Jennifer J D Morrissette; MacLean P Nasrallah; Jianhui Ma; Ciro Zanca; Andrew M Scott; Laura Orellana; Christos Davatzikos; Frank B Furnari; Donald M O'Rourke
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 6.  Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults.

Authors:  Floris P Barthel; Kevin C Johnson; Pieter Wesseling; Roel G W Verhaak
Journal:  Neurol Clin       Date:  2018-08       Impact factor: 3.806

7.  In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index.

Authors:  Spyridon Bakas; Hamed Akbari; Jared Pisapia; Maria Martinez-Lage; Martin Rozycki; Saima Rathore; Nadia Dahmane; Donald M O'Rourke; Christos Davatzikos
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

8.  Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Authors:  Josephine Kam Tai Dermawan; Masahiro Hitomi; Daniel J Silver; Qiulian Wu; Poorva Sandlesh; Andrew E Sloan; Andrei A Purmal; Katerina V Gurova; Jeremy N Rich; Justin D Lathia; George R Stark; Monica Venere
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

9.  Nicotinamide metabolism regulates glioblastoma stem cell maintenance.

Authors:  Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich
Journal:  JCI Insight       Date:  2017-05-18

10.  Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Authors:  Rebecca S Lescarbeau; Liang Lei; Katrina K Bakken; Peter A Sims; Jann N Sarkaria; Peter Canoll; Forest M White
Journal:  Mol Cancer Ther       Date:  2016-05-17       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.